![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Obesity Biology Unit, School of Clinical Sciences, University of Liverpool, Liverpool L69 3GA, UK
4 To whom correspondence should be addressed. E-mail: p.trayhurn{at}liverpool.ac.uk.
 |
ABSTRACT |
|---|
 TOP ABSTRACT LITERATURE CITED |
|---|
KEY WORDS: • adipocytes • adipokines • energy balance • inflammation • obesity
Obesity is now a considerable public health problem in most economically advanced countries. The prevalence of obesity in the U.K. (which is higher than that of most countries in Western Europe), for example, is such that 
25% of the adult population is now classified as obese on the basis of a BMI 
30 kg/m2 (1). The prevalence of the disorder is even higher in the United States, comprising 1 in 3 adults (2). The "obesity epidemic" has developed with considerable rapidity over the past 2 decades, with the incidence rising 3-fold in the U.K., for example, since the early 1980s (3). Obesity is associated with a reduction in life expectancy of 8 y, as well as with an increased risk of several major diseases, including type 2 diabetes, coronary heart disease, and certain cancers (such as breast and colon). In the case of type 2 diabetes, the risk is particularly marked because being obese increases the likelihood of developing the disease by 10-fold once a BMI of 30 kg/m2 is reached. Furthermore, the greater the degree of obesity, the higher the relative risk.
Although concern with obesity as a health problem has inevitably focused on humans, the disorder and the diseases with which it is associated are also a growing problem in our companion animals. However, in contrast to humans, an objective definition of obesity is lacking in cats and dogs, and the assessment is usually made on the basis of the "body condition score" (4). This, of course, involves a subjective element, unlike BMI, and the cut-off points for normal weight, overweight, and obesity are somewhat arbitrary with no clear reference to the amount of body fat or the threshold for the risk of type 2 diabetes and other associated diseases. As a consequence, estimates of the incidence of obesity in companion animals vary widely; in dogs, for example, these range from between 10 and 40% of the population (4–7).
We emphasize, however, that the human classification of obesity based on BMI is not without complications. Body builders, for example, have a high BMI in relation to body fat because of their large muscle mass, whereas the threshold for obesity of a BMI of 30 kg/m2, based primarily on Europeans and North Americans, is now recognized as inappropriate for some other population groups, such as those in South East Asia, where a lower cut-off value is increasingly employed. This is a reflection of the fact that for a given BMI, these populations are likely to have more abdominal fat and are therefore more likely to exhibit the deleterious metabolic consequences that accompany "central obesity" (8).
Regulation of energy balance
The growing concern with obesity has been the main impetus behind much recent research on the regulation of energy balance, reflecting the fact that it has been axiomatic that the disorder is fundamentally a problem of energy balance. Put simply, obesity can develop only when energy intake is in excess of energy expenditure, with the differences in input and output buffered primarily by changes in fat stores. There is an underlying genetic predisposition to obesity, with distinct differences between breeds of dog, for example, in the tendency to become obese. Genetic changes do not provide an explanation, however, for the present surge in the incidence of obesity in human populations (or in cats and dogs). The rise in obesity is, in practice, a consequence of changes in lifestyle (diet and the levels of physical activity) in both humans and companion animals.
At a mechanistic level, major developments have occurred recently in the control of energy balance through the identification of novel factors involved in appetite, such as ghrelin, orexin A, and the endogenous cannabinoid system (9–12). Similarly, important developments in our understanding of energy expenditure have come through the emergence of the concept of "nonexercise activity thermogenesis" (NEAT)5 (13), together with the discovery of new mitochondrial uncoupling proteins (UCP), primarily UCP2 and UCP3 (12). However, these novel uncoupling proteins are no longer thought to provide an immediate locus for adaptive thermogenesis in tissues outwith brown fat (14).
The primary buffering of energy intake and expenditure is through fatty acid deposition (as triacylglycerols) and release in white fat, an organ that until recently was considered a "poor relation" in energy balance and obesity research. However, this has changed radically over the past few years with the tissue becoming a focus of intense research activity. There are several reasons for this change in position: 1) obesity is defined by the expansion of the tissue, which therefore has to be central in the consideration of the disorder; 2) white adipose tissue (WAT) is the primary site of the production of key hormones involved in energy balance, notably leptin; 3) the tissue secretes a number of factors involved in a range of metabolic and physiological processes; some of these factors are implicated in the pathologies associated with obesity, particularly insulin resistance and the metabolic syndrome (15,16).
White adipose tissue
The apparent simplicity of both white adipocytes and of WAT itself, histologically and metabolically, is the key reason why the organ has been relatively ignored until recently. With triacylglycerols constituting up to 85% of tissue weight, it is not surprising that WAT was regarded as essentially limited in function to lipid synthesis and breakdown. The simplicity is, however, illusory. At the cellular level, there is considerable heterogeneity, with mature adipocytes accounting for no more than half of the total cell content of white fat, the tissue containing fibroblasts, endothelial cells, preadipocytes, and macrophages, for example (17–19). Complexity is also evident at the level of the basic process of glucose transport into white adipocytes; of the 14 members of the facilitative glucose transporter (GLUT) gene family (gene name SLC2A), as many as 8, GLUT1, GLUT3, GLUT4, GLUT5, GLUT8, GLUT10, GLUT12, and HMIT, are expressed in white adipocytes (20; Yao, Wood, and Trayhurn, unpublished observations). Thus, the process of sugar uptake into white adipocytes is thought to involve a range of different transport proteins, each with its own distinct kinetic characteristics, and at least one (GLUT4) displaying insulin sensitivity.
WAT is a major secretory organ, particularly through the release of fatty acids during fasting. The tissue also releases other lipid moieties, such as cholesterol, retinol, steroid hormones, and prostaglandins (21). Cholesterol and retinol are not synthesized by WAT, but rather are taken up and stored within the tissue. Steroid hormone conversions can take place in white adipocytes, such as the activation of 11-dehydrocorticosterone to corticosterone catalyzed by 11ß-hydroxysteroid dehydrogenase type 1 (22). The enzyme lipoprotein lipase is released from adipocytes for the breakdown of circulating triacylglycerols to fatty acids, which are subsequently stored within fat cells. In the late 1980s, a further secreted protein from adipocytes was identified, namely, adipsin, a complement-related factor (23,24). Adipsin was initially thought to be a direct signal in energy balance, but this was subsequently found not to be the case.
A major step forward in the recognition of the secretory role of WAT occurred in the early 1990s with the discovery that the proinflammatory cytokine tumor necrosis factor-
(TNF-) is synthesized and released by adipocytes (25). TNF- expression increases in obesity, and this cytokine plays an important role in the induction of insulin resistance (26,27). TNF- was shown to have extensive metabolic effects in adipose tissue, including the stimulation of lipolysis and apoptosis (28,29).
The pivotal change in perspective on the role of WAT as a secretory organ came with the identification of the hormone leptin in 1994 (30). This followed the search for the Ob gene, a mutation in which is responsible for the obesity of the ob/ob mouse (30). Leptin, a 16,000 MW cytokine-like protein, is a critical hormonal signal from adipocytes in the regulation of appetite and energy balance (21,31,32), interacting with several hypothalamic orexigenic and anorexigenic pathways. Thus, the neuropeptide Y, melanin-concentrating hormone, orexin A, agouti-related peptide, and cannabinoid systems have each been reported to be inhibited by leptin (33–37). In contrast, the key anorexigenic systems of pro-opiomelanocortin/melanocortin, cocaine- and amphetamine-regulated transcript, and corticotrophin-releasing hormone are upregulated by the hormone (33,34,37,38). These multiple effects of leptin result in a powerful suppression of food intake.
In addition to inhibiting intake, leptin plays a role in the regulation of energy expenditure; a potent example of this comes from overfeeding studies on normal and ob/ob mice. In one study, lean mice fed a "cafeteria diet" overate by 70% in energy terms with no additional energy deposition; this is a powerful illustration of the much debated phenomenon of diet-induced thermogenesis (39,40). Serendipitously, in this particular study, the energy intake of the lean mice fed the cafeteria diet was the same as that of ob/ob mice fed a standard laboratory diet. However, the rate of energy deposition of the obese was 3 times that of the lean (39). Thus, the ob/ob mutants lacking functional leptin had a greatly reduced capacity for diet-induced thermogenesis.
Adipokines
The identification of leptin led to the recognition that white fat is an important endocrine organ. Indeed, it is now evident that white adipocytes secrete a multiplicity of protein signals and factors (Fig. 1), termed adipokines (15,16,21,41). The diversity of the adipokines is considerable, in terms of both protein structure and function. The adipokines encompass classical cytokines (e.g., TNF-, IL-6), chemokines [e.g., monocyte chemoattractant protein-1 (MCP-1)], proteins of the alternative complement system (e.g., adipsin), and proteins involved in vascular hemostasis [e.g., plasminogen activator inhibitor-1 (PAI-1)], the regulation of blood pressure (angiotensinogen), lipid metabolism (e.g., cholesteryl ester transfer protein, retinol binding protein), glucose homeostasis (e.g., adiponectin), and angiogenesis [e.g., vascular endothelial growth factor (VEGF)].
|
A number of adipokines are linked to inflammation and the immune response (Fig. 1), and parallels have been drawn between adipocytes and immune cells. Indeed, preadipocytes are reported to be able to act like macrophages (44,45). The inflammation-related adipokines include cytokines, chemokines, and acute phase proteins (15,16,46). Clear evidence for the expression and secretion of the following cytokines and chemokines has been documented: TNF-, transforming growth factor-ß, IL-1ß, IL-6, IL-8, IL-10, MCP-1, and macrophage migration inhibitory factor. Acute phase proteins that have been clearly identified as adipokines are haptoglobin, serum amyloid-A, and plasminogen activator inhibitor-1 (PAI-1). PAI-1 is also, of course, a key agent in vascular hemostasis (47).
In addition to these factors, several other inflammation-related adipokines are recognized, including leptin, the angiogenic protein VEGF, and the first of the family of neurotrophins to be discovered, namely, nerve growth factor (NGF) (16,48,49). Importantly, the major adipocyte hormone adiponectin has an anti-inflammatory action (50) in addition to its role in insulin sensitivity and several other metabolic processes (51,52).
Inflammation in obesity
The expression and release of a number of inflammation-related adipokines, including IL-6, TNF, PAI-1, haptoglobin, and leptin (16), are increased in adipose tissue with obesity. There is, however, an important exception to this general pattern of increased production; the expression and circulating levels of adiponectin decline in obesity (53). Because adiponectin has an anti-inflammatory action (59), this exacerbates the extent to which adipose tissue is in a state of "inflammation" in the obese. Inflammation in WAT is now thought to be powerfully augmented in obesity through the infiltration of macrophages as tissue mass expands (18,19).
Inflammation is one of the most important developing areas in obesity biology; the obese state was recognized recently as characterized by chronic low-grade inflammation (54–57). The main basis for this view is that the circulating levels of several markers of inflammation, such as IL-6, IL-18, C-reactive protein, PAI-1, and haptoglobin, are elevated in obesity and are reduced with weight loss (54,56,58,59). Given that WAT secretes a wide range of inflammation-related adipokines, it is probable that the tissue is the source of at least some of the elevated plasma levels of these factors in the obese.
It is increasingly thought that the mild inflammatory state of obesity, and particularly the production of inflammatory adipokines, is important in the development of the diseases associated with a high BMI (60). In particular, insulin resistance, type 2 diabetes, and atherosclerosis, as well as other components of the metabolic syndrome, were causally linked to inflammation. This parallels the growing recognition of the importance of inflammation as an element in a wide range of diseases, including those associated with aging such as the dementias (61). However, much work must be done to unravel the mechanistic basis for the link between specific inflammatory adipokines and the metabolic syndrome.
The reason why obesity should be accompanied by inflammation has received little attention. We recently argued the parsimonious view that given the increased production of inflammation-related adipokines in WAT, the tissue is the main site of direct inflammation in obesity, and raised circulating levels of inflammatory markers reflect spillover from fat rather than serve as an indication of systemic inflammation (16). We argued further that this occurs as a response to hypoxia, proposing that as WAT mass expands in obesity, pockets of adipocytes distant from the vasculature become relatively low in oxygen (16). Hypoxia then leads to the stimulation of the production and release of inflammatory cytokines, chemokines, and angiogenic factors to stimulate blood flow and increase vascularization (16). This general proposal has parallels with the metabolic responses in wound healing and to the events within solid tumors (62), and involves the recruitment of the transcription factor hypoxia inducible factor-1, which is regarded as the molecular sensor of low oxygen tension (63,64).
Perspectives
The continuing increase in the incidence of obesity and its associated disorders in affluent populations will provide an ongoing focus for investigation of the fundamental mechanisms of energy regulation. The radical change in how white fat is viewed has led to adipose tissue biology becoming a "hot" area of biomedical research. White adipocytes are key endocrine and secretory cells that release a wide range of regulatory factors. There is extensive cross-talk between white adipocytes and other cells and tissues through both endocrine and paracrine signaling. The local communication between adipocytes and macrophages within WAT is critical in the inflammatory response exhibited in the tissue in obesity, and perhaps other situations in which body fat increases, particularly because of the link between inflammation and the metabolic syndrome. The cross-talk within WAT is likely to include preadipocytes as well as macrophages and mature adipocytes, and this will be central to the local regulation of adipogenesis.
The endocrine link between WAT and the hypothalamus through leptin is a critical component of the regulation of appetite and energy balance. There has been much interest in whether other adipokines also act centrally as signals in energy balance, with possible candidates including IL-6. However, there is recent evidence that adiponectin, a major adipocyte-derived hormone, plays a direct role in the regulation of energy balance. This pleiotropic adipokine reduces body weight and, intriguingly, appears to do so without affecting appetite, the central action involving stimulation of energy expenditure (65). The effect on expenditure may occur through the melanocortin system and involve, at least in part, an activation of brown adipose tissue thermogenesis (65).
Given the public health concern with obesity, most studies have inevitably focused directly on humans or laboratory rodents as models. Many of the concepts that have been established in these species are likely, however, to be applicable to companion animals. With a view to exploring the link between inflammation and obesity-associated diseases in dogs, we recently began exploring the extent to which canine adipose tissue synthesizes inflammatory adipokines. The early results indicate that the major canine WAT depots are able to express the genes encoding a range of adipokines, including adiponectin, leptin, IL-6, PAI-1, haptoglobin, NGF, and TNF (66). Furthermore, expression takes place in the adipocytes themselves, as demonstrated through fractionation of freshly isolated tissue and after differentiation of fibroblastic preadipocytes into mature adipocytes in primary culture (66). Thus, canine WAT appears similar to the human and rodent tissue in its ability to produce major inflammatory adipokines.
The similarities between the metabolic syndrome in dogs and humans (67), together with the availability of the canine genome sequence (68), suggest that rapid progress can be made in exploring the links among WAT, adipokines, inflammation, and metabolic disease in companion animals.
|
FOOTNOTES |
|---|
2 Author disclosure: Paul Trayhurn received travel and hotel expenses, and an honorarium, from the WALTHAM Centre for Pet Nutrition.
3 Supported by grants from the BBSRC, European Union (OB-Age: QLK6-CT-2002-02288), and the Broadgreen and Royal Liverpool University Hospital NHS Trust. We are grateful to our colleagues in the Obesity Biology Unit for their help and support.
5 Abbreviations used: MCP-1; monocyte chemoattractant protein-1; NEAT, nonexercise activity thermogenesis; NGF, nerve growth factor; PAI-1, plasminogen activator inhibitor-1; TNF, tumor necrosis factor-; VEGF, vascular endothelial growth factor; WAT, white adipose tissue.
|
LITERATURE CITED |
|---|
|
TOPABSTRACTLITERATURE CITED |
|---|
1. Rennie KL, Jebb SA. Prevalence of obesity in Great Britain. Obes Rev. 2005;6:11–2.[Medline]
2. Baskin ML, Ard J, Franklin F, Allison DB. Prevalence of obesity in the United States. Obes Rev. 2005;6:5–7.[Medline]
3. Prentice AM, Jebb SA. Obesity in Britain: gluttony or sloth? BMJ. 1995;311:437–9.
4. German, AJ. The growing problem of obesity in dogs and cats. J Nutr. 2006;136;1940S–6S.
5. Markwell PJ, Butterwick RF, Wills JM, Raiha M. Clinical studies in the management of obesity in dogs and cats. Int J Obes Relat Metab Disord. 1994;18: Suppl 1:S39–43.
6. Butterwick RF, Hawthorne AJ. Advances in dietary management of obesity in dogs and cats. J Nutr. 1998;128:2771S–5.
7. Hoenig M. Comparative aspects of diabetes mellitus in dogs and cats. Mol Cell Endocrinol. 2002;197:221–9.[Medline]
8. Shiwaku K, Anuurad E, Enkhmaa B, Nogi A, Kitajima K, Shimono K, Yamane Y, Oyunsuren T. Overweight Japanese with body mass indexes of 23.0–24.9 have higher risks for obesity-associated disorders: a comparison of Japanese and Mongolians. Int J Obes Relat Metab Disord. 2004;28:152–8.[Medline]
9. Harrold JA, Williams G. The cannabinoid system: a role in both the homeostatic and hedonic control of eating? Br J Nutr. 2003;90:729–34.[Medline]
10. Otto B, Spranger J, Benoit SC, Clegg DJ, Tschöp MH. The many faces of ghrelin: new perspectives for nutrition research? Br J Nutr. 2005;93:765–71.[Medline]
11. Wynne K, Stanley S, McGowan B, Bloom S. Appetite control. J Endocrinol. 2005;184:291–318.
12. Trayhurn P. The biology of obesity. Proc Nutr Soc. 2005;64:31–8.[Medline]
13. Levine JA, Kotz CM. NEAT—non-exercise activity thermogenesis—egocentric & geocentric environmental factors vs. biological regulation. Acta Physiol Scand. 2005;184:309–18.[Medline]
14. Dulloo AG, Seydoux J, Jacquet J. Adaptive thermogenesis and uncoupling proteins: a reappraisal of their roles in fat metabolism and energy balance. Physiol Behav. 2004;83:587–602.[Medline]
15. Rajala MW, Scherer PE. Minireview: the adipocyte —at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology. 2003;144:3765–73.
16. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr. 2004;92:347–55.[Medline]
17. Hausman GJ. The comparative anatomy of adipose tissue. In: Cryer A, Van RLR, editors. New perspectives in adipose tissue: structure, function and development. London: Butterworths; 1985. p. 1–21.
18. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112:1796–808.[Medline]
19. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003;112:1821–30.[Medline]
20. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003;89:3–9.[Medline]
21. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc. 2001;60:329–39.[Medline]
22. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS. A transgenic model of visceral obesity and the metabolic syndrome. Science. 2001;294:2166–70.
23. Cook KS, Min HY, Johnson D, Chaplinsky RJ, Flier JS, Hunt CR, Spiegelman BM. Adipsin: a circulating serine protease homolog secreted by adipose tissue and sciatic nerve. Science. 1987;237:402–5.
24. Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science. 1987;237:405–8.
25. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha—direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.
26. Spiegelman BM, Choy L, Hotamisligil GS, Graves RA, Tontonoz P. Regulation of adipocyte gene expression in differentiation and syndromes of obesity/diabetes. J Biol Chem. 1993;268:6823–6.
27. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409–15.[Medline]
28. Prins JB, Niesler CU, Winterford CM, Bright NA, Siddle K, O'Rahilly S, Walker NI, Cameron DP. Tumor necrosis factor-alpha induces apoptosis of human adipose cells. Diabetes. 1997;46:1939–44.[Abstract]
29. Gasic S, Tian B, Green A. Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing G(I) protein concentrations. J Biol Chem. 1999;274:6770–5.
30. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homolog. Nature. 1994;372:425–32.[Medline]
31. Harris RB. Leptin—much more than a satiety signal. Annu Rev Nutr. 2000;20:45–75.[Medline]
32. Rayner DV, Trayhurn P. Regulation of leptin production: sympathetic nervous system interactions. J Mol Med. 2001;79:8–20.[Medline]
33. Schwartz MW, Seeley RJ, Campfield LA, Burn P, Baskin DG. Identification of targets of leptin action in rat hypothalamus. J Clin Invest. 1996;98:1101–6.[Medline]
34. Meister B. Control of food intake via leptin receptors in the hypothalamus. Vitam Horm. 2000;59:265–304.[Medline]
35. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura GI, Palmiter RD, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822–5.[Medline]
36. Zhu Y, Yamanaka A, Kunii K, Tsujino N, Goto K, Sakurai T. Orexin-mediated feeding behavior involves both leptin-sensitive and -insensitive pathways. Physiol Behav. 2002;77:251–7.[Medline]
37. Wilding JP. Neuropeptides and appetite control. Diabet Med. 2002;19:619–27.[Medline]
38. Kristensen P, Judge ME, Thim L, Ribel U, Christjansen KN, Wulff BS, Clausen JT, Jensen PB, Madsen OD, et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature. 1998;393:72–6.[Medline]
39. Trayhurn P, Jones PM, McGuckin MM, Goodbody AE. Effects of overfeeding on energy balance and brown fat thermogenesis in obese (ob/ob) mice. Nature. 1982;295:323–5.[Medline]
40. Stock MJ. Gluttony and thermogenesis revisited. Int J Obes Relat Metab Disord. 1999;23:1105–17.[Medline]
41. Frühbeck G, Gómez-Ambrosi J, Muruzabal FJ, Burrell MA. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am J Physiol Endocrinol Metab. 2001;280:E827–47.
42. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, Hauner H, McCann SM, Scherbaum WA, Bornstein SR. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211–6.
43. Mark AL, Rahmouni K, Correia M, Haynes WG. A leptin-sympathetic-leptin feedback loop: potential implications for regulation of arterial pressure and body fat. Acta Physiol Scand. 2003;177:345–9.[Medline]
44. Cousin B, Munoz O, Andre M, Fontanilles AM, Dani C, Cousin JL, Laharrague P, Casteilla L, Penicaud L. A role for preadipocytes as macrophage-like cells. FASEB J. 1999;13:305–12.
45. Villena JA, Cousin B, Penicaud L, Casteilla L. Adipose tissues display differential phagocytic and microbicidal activities depending on their localization. Int J Obes Relat Metab Disord. 2001;25:1275–80.[Medline]
46. Trayhurn P. Adipose tissue in obesity—an inflammatory issue. Endocrinology. 2005;146:1003–5.
47. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord. 2004;28:1357–64.[Medline]
48. Peeraully MR, Jenkins JR, Trayhurn P. NGF gene expression and secretion in white adipose tissue: regulation in 3T3-L1 adipocytes by hormones and inflammatory cytokines. Am J Physiol Endocrinol Metab. 2004;287:E331–9.
49. Wang B, Jenkins JR, Trayhurn P. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-. Am J Physiol Endocrinol Metab. 2005;288:E731–40.
50. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H, Hotta K, Nishida M, Takahashi M, et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappa B signaling through a cAMP-dependent pathway. Circulation. 2000;102:1296–301.
51. Berg AH, Combs TP, Du X, Brownlee M, Scherer PE. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947–53.[Medline]
52. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7:941–6.[Medline]
53. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257:79–83.[Medline]
54. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19:972–8.
55. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab. 2000;85:3338–42.
56. Festa A, D'Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP, Haffner SM. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord. 2001;25:1407–15.[Medline]
57. Engström G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgarde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes. 2003;52:2097–101.
58. Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, Nicoletti G, Giugliano D. Weight loss reduces interleukin-18 levels in obese women. J Clin Endocrinol Metab. 2002;87:3864–6.
59. Chiellini C, Santini F, Marsili A, Berti P, Bertacca A, Pelosini C, Scartabelli G, Pardini E, Lopez-Soriano J, et al. Serum haptoglobin: a novel marker of adiposity in humans. J Clin Endocrinol Metab. 2004;89:2678–83.
60. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord. 2003;27: Suppl 3:S53–5.
61. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol. 2004;39:687–99.[Medline]
62. Höpfl G, Ogunshola O, Gassmann M. HIFs and tumors—causes and consequences. Am J Physiol Regul Integr Comp Physiol. 2004;286:R608–23.
63. Semenza GL. HIF-1 and mechanisms of hypoxia sensing. Curr Opin Cell Biol. 2001;13:167–71.[Medline]
64. Wenger RH. Cellular adaptation to hypoxia: O2-sensing protein hydroxylases, hypoxia-inducible transcription factors, and O2-regulated gene expression. FASEB J. 2002;16:1151–62.
65. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB, Scherer PE, Ahima RS. Adiponectin acts in the brain to decrease body weight. Nat Med. 2004;10:524–9.[Medline]
66. Eisele I, Wood IS, German AJ, Hunter L, Trayhurn P. Adipokine gene expression in dog adipose tissues and dog white adipocytes differentiated in primary culture. Horm Metab Res. 2005;37:474–81.[Medline]
67. Bergman RN, Van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP, Ellmerer M. Central role of the adipocyte in the metabolic syndrome. J Investig Med. 2001;49:119–26.[Medline]
68. Kirkness EF, Bafna V, Halpern AL, Levy S, Remington K, Rusch DB, Delcher AL, Pop M, Wang W, et al. The dog genome: survey sequencing and comparative analysis. Science. 2003;301:1898–903.
This article has been cited by other articles:
|
|
 |
|
  N. P. Hyland, A. P. Chambers, C. M. Keenan, Q. J. Pittman, and K. A. Sharkey Differential adipokine response in genetically predisposed lean and obese rats during inflammation: a role in modulating experimental colitis? Am J Physiol Gastrointest Liver Physiol, November 1, 2009; 297(5): G869 - G877. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Herse, Bai Youpeng, A. C. Staff, J. Yong-Meid, R. Dechend, and Zhou Rong Circulating and Uteroplacental Adipocytokine Concentrations in Preeclampsia Reproductive Sciences, June 1, 2009; 16(6): 584 - 590. [Abstract] [PDF]
|
|
|
|
 |
|
 S. A. Bayol, B. H. Simbi, J. A. Bertrand, and N. C. Stickland Offspring from mothers fed a 'junk food' diet in pregnancy and lactation exhibit exacerbated adiposity that is more pronounced in females J. Physiol., July 1, 2008; 586(13): 3219 - 3230. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zheng and H.-R. Berthoud Neural Systems Controlling the Drive to Eat: Mind Versus Metabolism Physiology, April 1, 2008; 23(2): 75 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Hausman, C. R. Barb, and R. G. Dean Patterns of gene expression in pig adipose tissue: Transforming growth factors, interferons, interleukins, and apolipoproteins J Anim Sci, October 1, 2007; 85(10): 2445 - 2456. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
